Abstract 335: Association of Amyloidosis With In-hospital & 30-day Outcomes Among Patients Hospitalized With Heart Failure

Objectives: Cardiac amyloidosis is an underdiagnosed cause of heart failure (HF). We investigated the prevalence and impact of amyloidosis in HF.

Methods: All hospitalizations for primary diagnosis of HF between January 1, 2010, and August 31, 2015 were identified in the National Readmission Database (NRD). Of these, hospitalizations with amyloidosis were matched in a 3:1 fashion to hospitalizations without amyloidosis using the year of admission, discharge quarter, age, sex, and Charlson comorbidity index. Primary outcomes of interest were inpatient mortality and 30-day readmission. Multivariable logistic regression models were used to estimate the association of HF with amyloidosis with adverse clinical outcomes.

Results: Overall, 2,846 (0.2%) hospitalizations had HF with amyloidosis. Hospitalizations for HF with amyloidosis had a higher prevalence of renal disease (56% vs. 45%), atrial fibrillation (48% vs 42%) and malignancy (20% vs 4%) as compared with HF without amyloidosis. In adjusted analyses, HF with amyloidosis had higher odds of in-hospital mortality (6% vs. 3%; OR 1.60, 95% CI 1.28, 2.00), 30-day readmission (OR 1.18, 95% CI 1.06, 1.32), and longer length of stay (CIE 1.73, 95% CI 1.44, 2.03). Among the HF with amyloidosis group, there were similar incidences of CV and non-CV-related readmissions (48% and 52%, respectively), but HF was the most common primary readmission diagnosis, constituting 35% of all readmissions. The incidence of inpatient mortality and 30-day readmission did not change significantly over time during the study period for either HF hospitalizations with or without amyloidosis.

Conclusion: In decompensated HF, presence of amyloidosis was associated with higher risk of inpatient mortality and 30-day readmission.